Black Diamond Therapeutics’ Post

🚀 Breaking Through The Noise: FibroGen's Resurgence 📈 FibroGen's latest phase 1 study spotlights their resilience and sparks new hope. Their anti-CD46 ADC, FG-3246, shows promise in advanced prostate cancer, with a notable median PFS of 8.7 months and significant PSA reductions. 🔬 Despite a streak of phase 3 disappointments, this new data is more than a glimmer of optimism. Compared with other therapies, FG-3246 seems to carve its own path, especially considering the study's heavily pre-treated demographic. It's a cautious yet pivotal stride towards potentially better treatment options for those facing metastatic castration-resistant prostate cancer. 🩺 As we await further clinical advancements, it's a reminder that the journey through drug development is fraught with setbacks, yet persistence can lead to significant breakthroughs. #Biotech #ProstateCancer #ClinicalTrials 🧬💼

The inability of cells to kill themselves is directly linked to both the development of cancer, and resistance to therapy. The major advances in mapping of cell death-associated signalling pathways that led to venetoclax being approved for use in the clinic – and an explosion of associated clinical trial activity – have now firmly established the pharmacological targeting of cell death pathways, including apoptosis and autophagy, as a crucial therapeutic approach in cancer treatment. Our infographic maps the signalling cascades involved in apoptosis and autophagy – highlighting major targets of drug intervention, highly sought-after therapeutic strategies and ongoing clinical trials. Check out the free infographic to learn more: https://okt.to/BFYwWU #Infographic #CellDeath #apoptosis #CancerResearch #ResearchChemicals

Apollomics presented vebreltinib data at the 2024 AACR meeting. Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer. Vebreltinib is a potent, small molecule, orally bioavailable, brain penetrating and highly selective c-MET inhibitor. It works by inhibiting the aberrant activation of the HGF/MET axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies such as osimertinib. By targeting MET dysregulation, vebreltinib offers a potential breakthrough for many cancers driven by MET alterations. #QMportolio #QMhealthcare #cancertreatment #AACR #apollomics #clinicalstudy https://lnkd.in/gCsyHXaP

Standard clinical trials for cancer drugs are expensive, lengthy, and often focused on advanced disease in which cures are unlikely. Arielle Medford, Ariel Carmeli, Alex Ritchie, Eric Lander, and Aparna Parikh propose a standing clinical trials platform to advance development of adjuvant therapies that prevent recurrence. Through this platform, patients after curative-intent therapy who show early molecular evidence of recurrence, based on circulating tumor DNA, would be invited to enroll in clinical trials that could be smaller and faster than conventional adjuvant trials. Read more in Nature Reviews Cancer. #BroadInstitute #Science #ScienceNews #Research #ScientificResearch

GlobalData Healthcare considers the growth of chimeric antigen receptor (CAR)-T therapy, a type of #immunotherapy that modifies patient's T-cells to destroy cancer. On our Insights page, read how a prominent biotech employed Judi for Eligibility and Judi for Adjudication on a pivotal Phase 2 CAR-T #oncology #clinicaltrial. Judi.io

Unlocking the Potential of Lurbinectedin: Exploring Other Cancers it Can TargetLurbinectedin, a promising anticancer agent, has shown significant promise in treating various types of cancer. As a potent inhibitor of transcriptional coactivator PC4, lurbinectedin has demonstrated efficacy in preclinical studies and clinical trials. But what other cancers can lurbinectedin target? In this article,... https://lnkd.in/exc53zxK

New publication shows Comprehensive Genomic Profilling (CGP), when compared to small panels, improves detection of actionable biomarkers and greater use of matched therapies, both of which were associated with significant increases in survival in patients with Advanced Non–Small Cell Lung Cancer (aNSCLC). Therefore, broadening the access and uptake of CGP testing enabling patients to receive molecularly driven precision therapies is paramount to improving outcomes in patients with aNSCLC. https://lnkd.in/dxpgc4zg

𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗺𝗲𝗱𝗶𝗮𝘁𝗼𝗿 𝗼𝗳 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝗱! A recent study that used our TRC research chemicals (TRC-M325750) identified a critical mediator of lung cancer drug resistance. Read the findings in the journal Oncogene: https://okt.to/em3Tn8 🌟Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/AL9bve #LungCancer #ProductCitation #oncologyresearch #ResearchChemicals

#DLL3 - A Target for Small Cell Lung Cancer Treatment DLL3, or Delta-like protein 3, is a cell surface protein involved in the #Notch signaling pathway, which regulates cell fate and development. It acts as a negative regulator, blocking Notch receptors from interacting with other ligands. DLL3 plays roles in tissue development, particularly in the nervous system, and is implicated in diseases like #cancer, where it's a potential therapeutic target, especially in small cell lung cancer. Read more: https://lnkd.in/eyUqgDTQ #ADC #cancerresearch

Overstimulate cancer to kill it 💥 In a new study, researchers used #ColorectalCancer cells and found that combining a drug that inhibits a #protein called PP2A with another drug blocking a cell cycle regulator called WEE1 sent cancer into overdrive, making it more vulnerable to treatment.   This approach could potentially be applied to other cancer models and drugs that activate abnormal cell growth pathways 🔍   Read more: https://lnkd.in/dndjcGUH ⬆️ Follow us for more health & #CancerResearch related insights.   #InnovativeTreatment #Insight #BGIGeneTest